Rubius Therapeutics is a biotechnology business based in the US. Rubius Therapeutics shares (RUBY) are listed on the PINK and all prices are listed in US Dollars. Rubius Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $0.02 |
| 200-day moving average | $0.02 |
| Wall St. target price | $1.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.99 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -46.63% |
| Return on equity TTM | -185.31% |
| Profit margin | 0% |
| Book value | $0.17 |
| Market Capitalization | $5.2 million |
TTM: trailing 12 months
We're not expecting Rubius Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Rubius Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Rubius Therapeutics's is 2.208. This would suggest that Rubius Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Rubius Therapeutics, Inc. , a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts. .
Learn how and where to buy Fannie Mae (FNMA) stock, view trends and see what may be ahead for share holders.
See how and where to buy Freddie Mac (FMCC) stock, view past price performance and learn what’s ahead for shareholders.
Direct indexing lets you replicate the performance of a specific index with potentially more tax efficiency. Learn how to get started here.
A deep dive into the highlights and limitations of Frec.
Explore the best bonuses for opening a new brokerage account.
It can help reduce taxes owed, but it’s not for beginners.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
The ins and outs of bundling stocks with this accessible investing option.
A deep dive into the highlights and limitations of Robinhood.